Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Shares Sold by LSV Asset Management

LSV Asset Management lessened its holdings in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) by 54.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 36,400 shares of the company's stock after selling 44,000 shares during the period. LSV Asset Management owned 0.08% of Amphastar Pharmaceuticals worth $1,352,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of AMPH. Wellington Management Group LLP purchased a new stake in shares of Amphastar Pharmaceuticals in the third quarter valued at approximately $957,000. Orion Portfolio Solutions LLC purchased a new stake in Amphastar Pharmaceuticals in the 3rd quarter valued at $239,000. Barclays PLC increased its stake in shares of Amphastar Pharmaceuticals by 53.3% in the 3rd quarter. Barclays PLC now owns 74,456 shares of the company's stock worth $3,613,000 after acquiring an additional 25,878 shares during the last quarter. Geode Capital Management LLC raised its holdings in shares of Amphastar Pharmaceuticals by 1.5% during the 3rd quarter. Geode Capital Management LLC now owns 920,363 shares of the company's stock worth $44,674,000 after acquiring an additional 14,015 shares during the period. Finally, Invst LLC boosted its position in shares of Amphastar Pharmaceuticals by 23.6% during the 3rd quarter. Invst LLC now owns 14,390 shares of the company's stock valued at $698,000 after acquiring an additional 2,752 shares during the last quarter. Institutional investors and hedge funds own 65.09% of the company's stock.

Amphastar Pharmaceuticals Trading Up 1.6 %

AMPH stock traded up $0.36 during mid-day trading on Friday, hitting $23.35. 735,039 shares of the company were exchanged, compared to its average volume of 462,779. The business has a fifty day simple moving average of $27.78 and a 200-day simple moving average of $37.36. The firm has a market capitalization of $1.11 billion, a P/E ratio of 7.78, a PEG ratio of 2.19 and a beta of 0.79. Amphastar Pharmaceuticals, Inc. has a 12-month low of $22.64 and a 12-month high of $53.96. The company has a quick ratio of 2.61, a current ratio of 3.43 and a debt-to-equity ratio of 0.82.

Insider Activity at Amphastar Pharmaceuticals

In related news, CFO William J. Peters sold 4,231 shares of the business's stock in a transaction on Tuesday, March 4th. The stock was sold at an average price of $27.54, for a total value of $116,521.74. Following the sale, the chief financial officer now owns 97,363 shares in the company, valued at approximately $2,681,377.02. The trade was a 4.16 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 27.10% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on the stock. Piper Sandler cut their price objective on shares of Amphastar Pharmaceuticals from $36.00 to $32.00 and set a "neutral" rating for the company in a research report on Friday, March 21st. Needham & Company LLC reaffirmed a "hold" rating on shares of Amphastar Pharmaceuticals in a research report on Thursday, April 10th.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.